-
Lancet Haematol丨HOPE-B Trial: Long-Term Follow-Up Results of Gene Therapy for Hemophilia B
Hemophilia B is characterized by a deficiency in clotting factor IX due to mutations in the F9 gene, impairing coagulation and increasing bleeding risk. Predominantly affecting males, hemophilia B can be classified as mild (factor IX activity >5% and
-
JCO丨EURO-SKI Study: Final Analysis and New Prognostic Factors for Treatment-Free Remission in CML
For chronic myeloid leukemia (CML) patients who achieve deep and durable molecular remission, the feasibility of discontinuing tyrosine kinase inhibitors (TKIs) has been established, challenging the notion of lifelong dependency on TKIs. Achieving treatment-free remission (TFR) without affecting overall survival (OS) is a key objective in current CML treatment. Recently, the Journal of Clinical Oncology…
-
ASCO China Voice | Two Studies by Professor Jiayu Wang from Academician Binghe Xu’s Team Selected for ASCO
The 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) will be held from May 31 to June 4 in Chicago, Eastern Time. Two studies led by Professor Jiayu Wang from Academician Binghe Xu’s team at the Cancer Hospital of the Chinese Academy of Medical Sciences (CAMS) have been selected for poster presentation…
-
Bearing Responsibility and Taking on Challenges—ILROG Leading the Future of the Lymphoma Field
With the rapid development of medical technology, modern lymphoma treatment has become a key focus in the field of oncology. From May 25 to 26, the Modern Lymphoma Treatment Academic Conference and the 5th International Lymphoma Radiation Oncology Group (ILROG) Continuing Education Annual Meeting were successfully held online. The conference featured thematic speeches, in-depth case…
-
ASCO Highlights丨Professor Guohai Shi: Finding a Needle in a Haystack – The Journey of Exploring Biomarkers for Kidney Cancer
In recent years, significant progress has been made in the treatment of renal cell carcinoma (RCC). However, selecting the appropriate treatment strategy remains a critical challenge. Traditional tumor markers have limited predictive value in RCC, making the search for new and reliable biomarkers to guide treatment decisions a hot topic in RCC research. As one…
-
ASCO Highlights丨Professor Guohai Shi: Finding a Needle in a Haystack – The Journey of Exploring Biomarkers for Kidney Cancer
In recent years, significant progress has been made in the treatment of renal cell carcinoma (RCC). However, selecting the appropriate treatment strategy remains a critical challenge. Traditional tumor markers have limited predictive value in RCC, making the search for new and reliable biomarkers to guide treatment decisions a hot topic in RCC research. As one…
-
ASCO China Voice丨Professor Nanlin Li: Efficacy and Safety Data of RC48 for Neoadjuvant Therapy in HER2-Positive Breast Cancer
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will take place in Chicago from May 31 to June 4. Led by Professor Nanlin Li from Xijing Hospital of the Air Force Medical University, a single-center, single-arm phase II clinical study focused on the efficacy and safety of the HER2-targeting antibody-drug conjugate (ADC) RC48…
-
Big Data, New Discoveries—The Key Role of Radiation Therapy in MZL and MALT Treatment
With the rapid development of medical technology, modern lymphoma treatment has become a key focus in the field of oncology. From May 25 to 26, the Modern Lymphoma Treatment Academic Conference and the 5th International Lymphoma Radiation Oncology Group (ILROG) Continuing Education Annual Meeting were successfully held online. The conference featured thematic speeches, in-depth case…
Connecting Medical Expertise through Media